

Application No. 10/777,792  
Amendment dated June 2, 2006  
Reply to the Restriction Requirement of March 2, 2006

### **REMARKS**

After entry of this amendment, claims 119-143 are pending, claims 1-118 having been canceled and claims 119-143 having been added. Support for new independent claims 119 and 131 is provided at, *e.g.*, paragraph [0077] and paragraph [0126] of the amended specification. Support for new claims 120 and 132 is provided at, *e.g.*, paragraph [0014] of the specification. Support for new claims 121-124 and 134-137 is provided at, *e.g.*, paragraph [0157] of the specification. Support for new claims 125-127 and 138-140 is provided at, *e.g.*, paragraph [0129] of the specification. Support for new claims 128-130 and 141-143 is provided at, *e.g.*, paragraph [0130] of the specification. Support for new claim 133 is provided at, *e.g.*, paragraphs [0016], [0162], [0163] and [0164] of the specification. Thus, the new claims contain no new matter. Cancellations of the claims are made to remove non-elected subject matter. Applicants reserve the right to pursue the non-elected subject matter in one or more divisional applications.

In the specification, support for the amendment to paragraph [0126] is found at, *e.g.*, page 5, lines 3-5 and original claim 48 of U.S. Patent Application No. 09/201,430, issued as U.S. Patent No. 6,787,523, which is incorporated by reference in the instant specification.

### **RESPONSE TO RESTRICTION REQUIREMENT**


In response to the Examiner's requirement, Applicants elect, without traverse, the claims of Group I, namely, original claims 69-78 and 102-103, which are drawn to a chimeric peptide comprising amyloid beta (A $\beta$ ) peptide and a T helper cell epitope. Applicants have canceled original claims 69-78 and 102-103 and have presented new claims 119-143. The new claims are directed to a pharmaceutical composition comprising A $\beta$ 1-7 linked to CRM197.

Application No. 10/777,792  
Amendment dated June 2, 2006  
Reply to the Restriction Requirement of March 2, 2006

The Examiner has required Applicants to elect a single disclosed species for prosecution, namely, SEQ ID NO:45, SEQ ID NO:46, SEQ ID NO:49, or SEQ ID NO:50. In light of the cancellation of claims 69-78 and 102-103, the election of a single species of the above-identified sequences is rendered moot. Applicants wish to draw the Examiner's attention that the new claims recite a single sequence, namely, A $\beta$ 1-7.

If the Examiner believes a telephone conference would expedite prosecution of this application, please telephone the undersigned at 650-625-8100.

Respectfully submitted,



Rosemarie L. Celli  
Registration No. 42,397

SUGHRUE MION, PLLC  
Telephone: (650) 625-8100  
Facsimile: (650) 625-8110

MOUNTAIN VIEW OFFICE

60032

CUSTOMER NUMBER

Date: June 2, 2006